Healthcare Jan 06, 2022 05:02 PM (GMT+8) · EqualOcean
In January 2022, yourui Pharmaceutical Technology (Shanghai) Co., Ltd. (hereinafter referred to as "yourui pharmaceutical") announced the acquisition of 100% equity of Zhongjian Pharmaceutical Co., Ltd. (hereinafter referred to as "Zhongjian pharmaceutical") held by Yinglian pharmaceutical holding group, Zhongjian pharmaceutical is the wholly-owned controlling shareholder of Zhuhai YINGLIAN Pharmaceutical Co., Ltd. (hereinafter referred to as "Zhuhai Yinglian") and Germany YINGLIAN Health Pharmaceutical Co., Ltd. (hereinafter referred to as "Germany Yinglian"), and Yikai capital acted as the exclusive financial adviser of Zhongjian pharmaceutical in this transaction. Yourui pharmaceutical, controlled by Kangqiao capital, is a biomedical company dedicated to the special medical market. It has mature commercial products and global innovative drug pipeline, focusing on the fields of respiration, pain management, emergency medicine and women and children. Zhongjian pharmaceutical is a leading pharmaceutical enterprise in China, with three mature commercial products and one product under research at the stage of listing review. The company has a mature sales system and regional coverage capacity, with a business team of more than 100 people, and a sales network covering about 3500 hospitals and about 6500 pharmacies in 29 provinces. Through this acquisition, yourui pharmaceutical will further strengthen its layout in the first aid field and retail market with the help of the existing product portfolio of Zhongjian pharmaceutical and its subsidiaries. At the same time, the company's mature sales system and sales experience will cooperate with the existing sales network and team of yourui medicine to help deepen and strengthen the sales network.

This text is a result of machine translation.